ASCO Guidelines Recommend Tamoxifen for 10 Years for Breast Cancer — Physician’s First Watch
ASCO Guidelines Recommend Tamoxifen for 10 Years for Breast Cancer
By Kelly Young
Tamoxifen is now recommended for 10 years instead of just 5 for women with hormone receptor–positive breast cancer, according to new guidelines from the American Society of Clinical Oncology published in the Journal of Clinical Oncology. Studies have shown improved survival with extended tamoxifen, as well as reduced risk for recurrence and contralateral breast cancer.
Women who are pre- or perimenopausal should begin with 5 years of tamoxifen. After that, if they are still pre- or perimenopausal, they should take tamoxifen for another 5 years. If they have become postmenopausal, however, they should be given the choice of tamoxifen or an aromatase inhibitor for 5 years.
Women who are postmenopausal at diagnosis should be offered the choice of 10 years of tamoxifen, 5 years of an aromatase inhibitor, or either 2–3 or 5 years of tamoxifen followed by up to 5 years of an aromatase inhibitor.